Omnipod 5: What You Need to Know About the Tubeless Pump System

The Omnipod 5 insulin pump received FDA approval in 2022, offering a tubeless option that works with continuous glucose monitoring. Here's what the approval means for people with Type 1 diabetes.

living with t1dtechnologysupport

Key takeaways

Omnipod 5 is a tubeless insulin pump system approved by the FDA for people with Type 1 diabetes age 6 and older
The system integrates with Dexcom G6 continuous glucose monitoring and a smartphone app for insulin delivery management
FDA approval was based on results from a clinical trial, though specific outcomes from that trial are not detailed in available summaries
Insurance coverage varies—approval depends on individual insurance plans, so availability is not guaranteed for all patients

What Is Omnipod 5?

Omnipod 5 is a tubeless insulin pump system that received FDA clearance in June 2022. Unlike traditional insulin pumps that use tubing to deliver insulin from a separate reservoir, the Omnipod 5 is a small, wearable pod that delivers insulin directly from the device itself. It represents a different approach to insulin delivery for people managing Type 1 diabetes.

How It Works With Your Glucose Monitor

The Omnipod 5 system is designed to work alongside the Dexcom G6 continuous glucose monitor (CGM). Users manage the system through a smartphone app that communicates with both the pump and their glucose readings. This integration allows for coordinated insulin delivery based on real-time blood sugar information.

Who Can Use It

The FDA approved Omnipod 5 for people with Type 1 diabetes age 6 and older. While the system may also be used for Type 2 diabetes in some cases, approval and use require both doctor approval and insurance authorization. Insurance coverage is not automatic—each case depends on individual insurance plans.

What Evidence Supports It

FDA clearance of Omnipod 5 was based on results from a clinical trial, though detailed findings from that research are not available in summary form here. If you're considering this system, talking with your healthcare team about the trial data and how it might apply to your situation is an important step.

Evidence label

Origin: YouTube / SugarMD (Video report). Evidence: Video report — unverified, pending corroboration. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

More evidence-labeled coverage across the Type1Cure library.